Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

Author： Forst Thomas Pfützner Andreas

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.1, 2012-01, pp. : 101-110

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A Lamos Elizabeth M Davis Stephen N

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

By Pratley Richard E

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor

Current Drug Targets, Vol. 13, Iss. 7, 2012-06 ,pp. : 970-983

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

By Deacon Carolyn F Holst Jens J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2047-2058

Informa Healthcare

Access to resources Recommend Favorite

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

By Fujii Yuki Abe Masanori Higuchi Terumi Mizuno Mari Suzuki Hiroko Matsumoto Shiro Ito Midori Maruyama Noriaki Okada Kazuyoshi Soma Masayoshi

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 259-267

Informa Healthcare

Access to resources Recommend Favorite